Live
- Tributes pour in for Late Dr. Manmohan Singh
- Heightened Security for Allu Arjun’s Virtual Court Hearing Amid Sandhya Theatre Case
- ChatGPT and Sora Outage: Services Restored After Hours of Downtime
- WhatsApp iOS Update: WhatsApp Brings AR Effects, Video Backgrounds and Document Scanning
- The advantages of buying a luxury villa in a community development
- Mufasa: The Lion King Roars to Success with INR 74 Crores in Its Opening Week in India
- CM Revanth Reddy Expresses Grief Over the Demise of Dr. Manmohan Singh
- Virat Kohli Encountered by Fan During Melbourne Test: Security Rushes In
- Telugu cinema struggling in the absence of Dasari
- Allu Arjun to Appear in Virtual Court Hearing Along with Sureties in Sandhya Theatre Case
Glenmark Pharma unveils asthma drug Indamet
It offers an affordable treatment option for adults and adolescents 12 yrs of age and older suffering from uncontrolled asthma
New Delhi: Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma. The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet.
The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily. "Respiratory is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients.
"We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma," Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement.
The drug maker is the first company in India to market the FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid, approved by the DCGI (Drug Controller General of India), the company noted. Asthma affects more than 34 million people in India, causing thousands of deaths every year.
